Mar 16, 2026 | Uncategorized
Subst Use Addctn J. 2026 Mar 17:29767342261421746. doi: 10.1177/29767342261421746. Online ahead of print.ABSTRACTBACKGROUND: Harm reduction services fulfill a critical need in reducing the negative consequences associated with the overdose crisis. However, many...
Mar 15, 2026 | Uncategorized
J Pain. 2026 Mar 13:106220. doi: 10.1016/j.jpain.2026.106220. Online ahead of print.ABSTRACTSingle session interventions (SSIs) for chronic pain are a novel and scalable intervention approach that are far less burdensome than typical 8-session behavioral treatments,...
Mar 15, 2026 | Uncategorized
JAMA Netw Open. 2026 Mar 2;9(3):e260667. doi: 10.1001/jamanetworkopen.2026.0667.NO ABSTRACTPMID:41838008 | DOI:10.1001/jamanetworkopen.2026.0667
Mar 11, 2026 | Uncategorized
J Addict Med. 2026 Mar 12. doi: 10.1097/ADM.0000000000001675. Online ahead of print.ABSTRACTOBJECTIVES: In 2022, the FDA issued a drug safety communication based on case studies that transmucosal buprenorphine, a medication for opioid use disorder (MOUD), may...
Mar 10, 2026 | Uncategorized
JMIR Form Res. 2026 Mar 11;10:e86070. doi: 10.2196/86070.ABSTRACTBACKGROUND: Approximately 45% of individuals taking methadone or buprenorphine have chronic pain. These medications are commonly prescribed for chronic pain or opioid use disorder (OUD). To optimize pain...
Feb 24, 2026 | Uncategorized
Am J Addict. 2026 Feb 25. doi: 10.1111/ajad.70151. Online ahead of print.ABSTRACTBACKGROUND AND OBJECTIVES: Patients using fentanyl have worse treatment outcomes; however, little is known about other drugs that complicate treatment.METHODS: A national survey (n = 396)...
